Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of IGF-1R/AS ODN Treated Autologous Tumor Cells in Newly Diagnosed Malignant Glioma
NCT02507583Phase 1Completed
- Start
- Sep 2015
- Primary completion
- Mar 2018
- Modality
- Whole Cell Cancer Vaccines, Device-based Delivery, Modified DNA Oligonucleotides
- Countries
- 1
01
Overview
Phase 1, open-label trial of IGV-001 in malignant glioma. Primary endpoint: Adverse Events at 36 months. Started Sep 2015; status: completed.
02
Drugs
IGV-001
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT02507583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02507583.